AMRI names quality control director for troubled plant, following lead of J&J, Novartis, others

Another pharmaceutical manufacturer has announced that it is beefing up quality control management after running afoul of FDA inspectors. AMRI ($AMRI) has named Tom McGrath as director of quality for aseptic services at its Burlington, MA, facility, which last year was cited in an FDA warning letter. A string of companies including Johnson & Johnson ($JNJ), Novartis ($NVS) and Hospira ($HSP) have recently named new leaders ranging from the plant level to the executive suite, whose focus, at least in part, will be on improving GMP in plants. Release | Story

Suggested Articles

A biotech that worked with a nutritional products maker on the API for its clinical-stage radiation drug, is buying all of the manufacturing know-how.

Merck KGaA is selling a manufacturing site and its Allergopharma allergy drug business as it focuses on newer meds.

In a first, the FDA and Indian oversight agencies worked together to block illegal drugs from entering the U.S.